NCT00093743View on ClinicalTrials.gov

Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

January 31, 2000

Primary Completion Date

September 30, 2007

Conditions
Adult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Acute Myeloid Leukemia in RemissionChildhood Myelodysplastic SyndromesFanconi AnemiaPreviously Treated Myelodysplastic Syndromes
Interventions
DRUG

fludarabine phosphate

Given IV

DRUG

cyclosporine

Given IV or PO

RADIATION

total-body irradiation

Undergo TBI

PROCEDURE

allogeneic bone marrow transplantation

Undergo allogeneic bone marrow transplantation

PROCEDURE

allogeneic hematopoietic stem cell transplantation

Undergo allogeneic PBSC transplantation

PROCEDURE

peripheral blood stem cell transplantation

Undergo allogeneic PBSC transplantation

DRUG

mycophenolate mofetil

Given PO or IV

Trial Locations (5)

37232

Vanderbilt-Ingram Cancer Center, Nashville

46202

Riley Hospital for Children, Indianapolis

60611

Robert H. Lurie Comprehensive Cancer Center, Chicago

84112

Huntsman Cancer Institute/University of Utah, Salt Lake City

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors
collaborator

National Heart, Lung, and Blood Institute (NHLBI)

NIH

collaborator

National Cancer Institute (NCI)

NIH

lead

Fred Hutchinson Cancer Center

OTHER

NCT00093743 - Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia | Biotech Hunter | Biotech Hunter